Diverse Manifestations of Sickle Cell Disease

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Sickle Cell Disease Across the Life Span: What Your Patients Want You to Know

Diverse Manifestations of Sickle Cell Disease

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    Sickle cell disease (SCD) imposes a substantial and life-long healthcare burden on patients coupled with psychosocial and financial burdens on patients and their caregivers. Current treatment approaches, while beneficial, are not curative, and often fail to overcome painful and at times life-threatening crises. While dramatic changes to treatment are on the horizon, their wide availability and long-term outcomes remain unknown. Join Drs. Andemariam and Freiermuth as they evaluate this new landscape from both the hematology and emergency medicine points of view.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Biree Andemariam, MD
    Professor of Medicine
    Division of Hematology/Oncology
    Director, New England Sickle Cell Institute
    Director, Connecticut Bleeding Disorders Center
    University of Connecticut Health
    Farmington, CT

    Consulting Fees: Accordant, Afimmune, Agios, Bluebird Bio, Emmaus, Forma Therapeutics, GlaxoSmithKline, Global Blood Therapeutics, Hemanext, Novartis, NovoNordisk, Sanofi Genzyme, Vertex

    Research: American Society of Hematology, Connecticut Department of Public Health, Forma Therapeutics, Global Blood Therapeutics, Hemanext, HRSA, Novartis, PCORI

    Caroline E. Freiermuth, MD
    Associate Professor of Emergency Medicine
    University of Cincinnati
    Cincinnati, OH

    Consulting Fees: CSL Behring

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel has nothing to disclose.
    • Keith Johnson has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mara Siegel has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize the lifelong physical and psychosocial burden that the various genotypes of sickle cell disease (SCD) impose on patients and their caregivers
    • Formulate a comprehensive, evidence-based approach to treating SCD at all degrees of severity using current and emerging therapies in appropriately selected patients
    • Discuss the common multi-organ comorbidities and complications associated with SCD
    • Develop an interdisciplinary strategy for managing SCD and its sequelae as patients transition through multiple care settings across the stages of life
  • Target Audience

    This activity is designed to meet the educational needs of hematologists, emergency medicine specialists, and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Vertex.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule20 Jul 2024